BR102017015071A2 - recombinant peptides associated with tuberculosis, use and diagnostic composition - Google Patents

recombinant peptides associated with tuberculosis, use and diagnostic composition Download PDF

Info

Publication number
BR102017015071A2
BR102017015071A2 BR102017015071A BR102017015071A BR102017015071A2 BR 102017015071 A2 BR102017015071 A2 BR 102017015071A2 BR 102017015071 A BR102017015071 A BR 102017015071A BR 102017015071 A BR102017015071 A BR 102017015071A BR 102017015071 A2 BR102017015071 A2 BR 102017015071A2
Authority
BR
Brazil
Prior art keywords
tuberculosis
recombinant peptides
diagnostic composition
peptides associated
recombinant
Prior art date
Application number
BR102017015071A
Other languages
Portuguese (pt)
Inventor
Ueira Vieira Carlos
De Almeida Araújo Santos Fabiana
Ricardo Goulart Filho Luiz
Duarte Da Silva Moraes Léa
Marquez Cunha Thúlio
Original Assignee
Fapemig Fund De Amparo A Pesquisa Do Estado De Minas Gerais
Univ Federal De Uberlandia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fapemig Fund De Amparo A Pesquisa Do Estado De Minas Gerais, Univ Federal De Uberlandia filed Critical Fapemig Fund De Amparo A Pesquisa Do Estado De Minas Gerais
Priority to BR102017015071A priority Critical patent/BR102017015071A2/en
Publication of BR102017015071A2 publication Critical patent/BR102017015071A2/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

peptídeos recombinantes associados à tuberculose, uso e composição diagnóstica. a presente invenção refere-se à seleção, caracterização e utilização de peptídeos recombinantes que mimetizam proteínas antigênicas de mycobacterium tuberculosis, agente etiológico da tuberculose (tb). os peptídeos recombinantes foram selecionados pela técnica de phage display, utilizando uma biblioteca comercial phd-12 contra imunoglobulina a (iga) de saliva de indivíduos com tuberculose. os clones selecionados, sequenciados, traduzidos e sintetizados quimicamente foram avaliados quanto as potenciais aplicações diagnósticas. são aplicáveis como sondas, através de ensaios imunológicos, comumente utilizados em laboratórios e para fins terapêuticos.recombinant peptides associated with tuberculosis, use and diagnostic composition. the present invention relates to the selection, characterization and use of recombinant peptides that mimic antigenic proteins of mycobacterium tuberculosis, the etiological agent of tuberculosis (tb). recombinant peptides were selected using the phage display technique, using a commercial library phd-12 against immunoglobulin a (iga) from saliva of individuals with tuberculosis. the selected clones, sequenced, translated and chemically synthesized were evaluated for potential diagnostic applications. they are applicable as probes, through immunological tests, commonly used in laboratories and for therapeutic purposes.

BR102017015071A 2017-07-13 2017-07-13 recombinant peptides associated with tuberculosis, use and diagnostic composition BR102017015071A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR102017015071A BR102017015071A2 (en) 2017-07-13 2017-07-13 recombinant peptides associated with tuberculosis, use and diagnostic composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102017015071A BR102017015071A2 (en) 2017-07-13 2017-07-13 recombinant peptides associated with tuberculosis, use and diagnostic composition

Publications (1)

Publication Number Publication Date
BR102017015071A2 true BR102017015071A2 (en) 2020-04-28

Family

ID=70547251

Family Applications (1)

Application Number Title Priority Date Filing Date
BR102017015071A BR102017015071A2 (en) 2017-07-13 2017-07-13 recombinant peptides associated with tuberculosis, use and diagnostic composition

Country Status (1)

Country Link
BR (1) BR102017015071A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021258179A1 (en) * 2020-06-26 2021-12-30 Universidade Federal de Uberlândia Synthetic mimotope peptides of an antigenic protein from m. tuberculosis, recombinant antibody or fragment thereof, aptamers, use thereof in the diagnosis of tuberculosis and method of diagnosis of tuberculosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021258179A1 (en) * 2020-06-26 2021-12-30 Universidade Federal de Uberlândia Synthetic mimotope peptides of an antigenic protein from m. tuberculosis, recombinant antibody or fragment thereof, aptamers, use thereof in the diagnosis of tuberculosis and method of diagnosis of tuberculosis

Similar Documents

Publication Publication Date Title
CL2021000716A1 (en) Antibody constructs for flt3 and cd3. (divisional sol. 201800269)
BR122020006918B8 (en) ANTI-STAT3 SINGLE DOMAIN ANTIBODY AND ITS USE, IN VITRO METHODS FOR MEASURING SAID ANTIBODY LEVELS AND FOR DIAGNOSING A DISORDER MEDIATED BY AN INTRACELLULAR COMPONENT, ISOLATED POLYPEPTIDE, AND COMPOSITION COMPRISING SUCH ANTIBODY OR ISOLATED POLYPEPTIDE
CL2020003416A1 (en) Bispecific antibody constructs that bind mesothelin and cd3 (divisional sol. 201800268)
CL2019000668A1 (en) Antibodies against alpha regulatory signal protein and use procedures.
BR112018002844A2 (en) single domain antibody-based chimeric antigen receptors and methods of use
AR101669A1 (en) ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
PE20191813A1 (en) ANTI-ILT4 ANTIBODIES AND ANTIGEN BINDING FRAGMENTS
BR112018015670A2 (en) Bispecific t-cell antibody constructs
BR112016013347A8 (en) anti-il-33 neutralizing human monoclonal antibody, pharmaceutical composition, cytokine expression inhibitor, epitope, nucleic acid molecule, vector, host cell, method of production and use thereof.
BR112018074463A2 (en) anti-tim-3 antibodies and methods of use.
BR112018001683A2 (en) recombinant adenovirus, composition, use of an adenovirus or composition, and non-human simian adenovirus.
BR112019008351A2 (en) immunoglobulins and their uses
BRPI0909123B8 (en) monoclonal antibodies, expression vector, host cell, pharmaceutical composition, use of said antibody, diagnostic kit and assay methods to detect the presence of influenza a virus epitopes
BR112013004288A2 (en) galenic forms of multiple epitopes directed to induce an immune response to antigens.
BR112016019836A2 (en) method for analyzing a subject sample, diagnostic device for use in diagnosing endometriosis, kit, use of a biomarker, and method for increasing an antibody response in a subject
BR112019012796A2 (en) antineuropillin antigen binding proteins and methods of use thereof
BR112017006598A2 (en) human derived antidipeptide repeat antibody (dprs)
BR112016017764A2 (en) broad spectrum antidengue antibody
BR112017014559A2 (en) il-17a binding polypeptide, fusion or conjugated protein, complex, polynucleotide encoding a polypeptide, and, composition
BR112019010128A2 (en) anti-gitr antigen binding proteins and methods of use thereof
BR112015008036A2 (en) isolated peptide population, method for detecting antibody in a sample, method for diagnosing monocytic and / or granulocytic erlichiosis, and kit
BR112021012667A2 (en) Anti-pd-1 binding proteins and methods of using them
BR112022027096A2 (en) COMPOSITIONS AND METHODS RELATED TO ACTIVATED THERAPEUTIC AGENTS
BR112018008840A2 (en) single domain antibodies directed against intracellular antigens
UY37757A (en) COMPOSITIONS, PROCEDURES AND / OR KITS THAT INCLUDE AN EXTRACELLULAR DOMAIN OF RECOMBINANT HUMAN CD38

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.